| Bid | 0.78 |
| Market Cap | 52.64M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | -0.62 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.81 |
| Volume | 49,329 |
| Avg. Volume (20D) | 377,113 |
| Open | 0.78 |
| Previous Close | 0.79 |
| Day's Range | 0.78 - 0.84 |
| 52-Week Range | 0.66 - 1.95 |
| Beta | undefined |
About IOBT
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and ne...
Analyst Forecast
According to 3 analyst ratings, the average rating for IOBT stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 1151.56% from the latest price.
11 months ago · 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to...
